SGLT2 inhibitors exert renoprotective effects in both diabetic and non-diabetic CKD patients by reducing intraglomerular pressure, optimizing glycemic control, decreasing body weight, ameliorating anemia, and reducing plasma uric acid levels [3, 4, 10, 13–15]. The gene discussed is SLC5A2; the disease is anemia (phenotype).